Literature DB >> 17912148

Kaposi's sarcoma: a model of both malignancy and chronic inflammation.

J L Douglas1, J K Gustin, B Dezube, J L Pantanowitz, A V Moses.   

Abstract

Kaposi's sarcoma (KS) is a complex cancer characterized by angioproliferative multifocal tumors of the skin, mucosa and viscera. KS lesions are comprised of both distinctive spindle cells of endothelial origin and a variable inflammatory infiltrate. There are four different epidemiological forms of KS: classic (sporadic), African (endemic), AIDS-associated (epidemic), and immunosupression-associated (iatrogenic). Although these various forms of KS have different environmental and immunological components, the development of each depends upon infection with Kaposi's sarcoma herpesvirus/human herpesvirus-8 (KSHV/HHV8). KSHV encodes an arsenal of gene products that induce cellular proliferation, transformation, cell signaling, cytokine production, immune evasion, antiapoptosis and angiogenesis. Yet, KSHV alone is insufficient to give rise to KS. The exact origin of the tumor cell (spindle cell), which is generally agreed to be a type of endothelial cell, remains elusive. Current evidence supports their derivation from lymphatic endothelium. However, both lymphatic and vascular endothelial cell types can be infected by KSHV in vitro, and recent studies suggest that this virus may reprogram the target cell, thus masking the cell's true origin. It is also possible that the original target cell is an uncommitted progenitor. In addition to the potentially neoplastic spindle cells, the KS lesion also contains dendritic cells, macrophages, plasma cells and lymphocytes. The presence of this admixed immune infiltrate has led to the suggestion that KS may result from reactive hyperproliferation induced by chronic inflammation, and that it is therefore not a true neoplasm. This review details the data that support KS as a model of both oncogenesis and chronic inflammation.

Entities:  

Mesh:

Year:  2007        PMID: 17912148

Source DB:  PubMed          Journal:  Panminerva Med        ISSN: 0031-0808            Impact factor:   5.197


  22 in total

Review 1.  Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin?

Authors:  Berna C Özdemir; Gian-Paolo Dotto
Journal:  Trends Cancer       Date:  2017-03-06

2.  Characterization of entry and infection of monocytic THP-1 cells by Kaposi's sarcoma associated herpesvirus (KSHV): role of heparan sulfate, DC-SIGN, integrins and signaling.

Authors:  Nagaraj Kerur; Mohanan Valiya Veettil; Neelam Sharma-Walia; Sathish Sadagopan; Virginie Bottero; Arun George Paul; Bala Chandran
Journal:  Virology       Date:  2010-08-01       Impact factor: 3.616

3.  Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells.

Authors:  Fengchun Ye; Ali Abdul Lattif; Jianping Xie; Aaron Weinberg; Shoujiang Gao
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

4.  Kaposi's sarcoma-associated herpesvirus infection promotes differentiation and polarization of monocytes into tumor-associated macrophages.

Authors:  Natarajan Bhaskaran; Santosh K Ghosh; Xiaolan Yu; Sanhai Qin; Aaron Weinberg; Pushpa Pandiyan; Fengchun Ye
Journal:  Cell Cycle       Date:  2017-07-27       Impact factor: 4.534

5.  Piracy of prostaglandin E2/EP receptor-mediated signaling by Kaposi's sarcoma-associated herpes virus (HHV-8) for latency gene expression: strategy of a successful pathogen.

Authors:  Arun George Paul; Neelam Sharma-Walia; Nagaraj Kerur; Carl White; Bala Chandran
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

6.  Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen reduces interleukin-8 expression in endothelial cells and impairs neutrophil chemotaxis by degrading nuclear p65.

Authors:  Xiaofan Li; Deguang Liang; Xianzhi Lin; Erle S Robertson; Ke Lan
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

7.  Kaposin-B enhances the PROX1 mRNA stability during lymphatic reprogramming of vascular endothelial cells by Kaposi's sarcoma herpes virus.

Authors:  Jaehyuk Yoo; Jinjoo Kang; Ha Neul Lee; Berenice Aguilar; Darren Kafka; Sunju Lee; Inho Choi; Juneyong Lee; Swapnika Ramu; Juergen Haas; Chester J Koh; Young-Kwon Hong
Journal:  PLoS Pathog       Date:  2010-08-12       Impact factor: 6.823

8.  Primary Kaposi sarcoma of the subcutaneous tissue.

Authors:  Liron Pantanowitz; John Mullen; Bruce J Dezube
Journal:  World J Surg Oncol       Date:  2008-09-02       Impact factor: 2.754

9.  Induction of CCL20 production by Kaposi sarcoma-associated herpesvirus: role of viral FLICE inhibitory protein K13-induced NF-kappaB activation.

Authors:  Vasu Punj; Hittu Matta; Sandra Schamus; Tianbing Yang; Yuan Chang; Preet M Chaudhary
Journal:  Blood       Date:  2009-03-26       Impact factor: 22.113

10.  A systems biology approach to identify the combination effects of human herpesvirus 8 genes on NF-kappaB activation.

Authors:  Andreas Konrad; Effi Wies; Mathias Thurau; Gaby Marquardt; Elisabeth Naschberger; Sonja Hentschel; Ramona Jochmann; Thomas F Schulz; Holger Erfle; Benedikt Brors; Berthold Lausen; Frank Neipel; Michael Stürzl
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.